Apr 07,2015

Medtronic invests $2M in DreaMed

Medical equipment giant Medtronic has invested $2 million in DreaMed Diabetes, an Israeli startup company that develops a new delivery system of insulin. DreaMed has signed an exclusive development and license agreement with Medtronic for the development and marketing of products incorporating DreaMed’s technology in Medtronic’s insulin pumps. DreaMed was founded in 2014 by Eran Atlas and Shahar Miller.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Apr 14,2015

Hygieia Raises $675K in Debt Financing

Hygieia received $675,000 funding in the debt financing round according to the SEC form registered.

FUNDING DEBT FUNDING
View Analyst & Ambassador Comments
Go to original news
Jul 10,2015

Intuity Medical Raises $2M in Debt and Equity Round

Intuity Medical received $2 million in debt and equity rounds according to the SEC form registered.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Jul 31,2015

Welldoc Raises $225K in Debt Round

Welldoc registered a SEC form stating the debt financing of $225,000.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Aug 04,2015

Senseonics raises $10M for implanted, smartphone-connected glucose sensor

Germantown, Maryland-based continuous glucose monitor device maker Senseonics raised $10 million, according to an SEC filing. Existing investors include Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, and New Enterprise Associates. This brings the company’s total funding to at least $94 million to date.

FUNDING VENTURE ROUND
View Analyst & Ambassador Comments
Go to original news
Aug 19,2015

Fit4D Raises Series A Funding From SJF Ventures, Sovereign Health System and Blue Cross and Blue Shield of Nebraska

Fit4D (now named Cecelia Health), a digital health company that is improving the health of people with diabetes, announced today that it has secured Series A funding from SJF Ventures, Sovereign Health System and Blue Cross and Blue Shield of Nebraska. The funding will enable the company to expand distribution of its innovative diabetes platform across new customer channels and to leverage the platform to improve health outcomes for other chronic diseases.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Sep 01,2015

CeQur Announces $100 Million Series C Financing

CeQur SA, a leader in simple insulin infusion for people with diabetes, today announced a Series C financing of $100 million. The financing will support further clinical and regulatory activities, manufacturing scale-up and commercial operations for the 2016 first commercial launch of PaQ®, the Company's fully optimized second-generation three-day insulin infusion device.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Sep 16,2015

Omada Health, Which Pioneered Digital Therapeutics, Raises $48 Million In Series C Round

Omada Health, which provides a digital program based on the landmark NIH diabetes prevention study, raised $48 million, bringing total funding to $77.5 million. The series C round was led by Norwest Venture Partners, and includes returning investors Andreessen Horowitz and US Venture Partners, among others. Accelerator-turned venture fund Rock Health which nurtured Omada in its first class of digital health startups, also reinvested.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Dec 08,2015

One Medical nabs $65M, plans Brooklyn expansion

One Medical Group, the innovative tech-infused primary care medical group led by Tom Lee, M.D., has raised $65 million in capital to fuel "accelerated market expansion." The new funding was led by J.P. Morgan Asset Management on behalf of PEG Digital Growth Fund II LP and AARP Innovation Fund LP, One Medical said in a press release today. Unnamed current and new institutional investors and unnamed individual investors also participated.

FUNDING PRIVATE EQUITY ROUND
View Analyst & Ambassador Comments
Go to original news
Jan 04,2016

GlySens Incorporated Secures $20M Series D Investment to Advance its Fully Implanted, Long-Term Continuous Glucose Monitoring System

GlySens Incorporated announced today that it has closed a $20M Series D financing led by prior investors from its Series C round, in addition to significant participation from new investors.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES